Transcatheter aortic valve implantation (TAVi)

Medtronic real-world results

The CoreValve™/Evolut™ platform provides reproducible results from clinical trial to the real world.  

Explore our STS/ACC TVT Registry™* data that supports the excellent clinical performance seen in our trials.

  

Older man in a red jacket and hat outside in a forest smiling
Alert Indications, Safety, and Warnings

FORWARD Study1

This multicenter, prospective, single-arm, observational post-market study evaluated the safety and performance of the Evolut™ R system in a routine hospital setting.

  • Study Status/Duration: 12-month outcomes reported/3-year follow-up
  • Sample Size: N = 1040
  • Devices: Evolut™ R TAV

1 year hemodynamic data
Valve Performance

SEE DATA

30-day procedural outcomes
All Cause Rates

ADVANCE Study2

ADVANCE is a multicenter, prospective, single-arm, observational study to evaluate safety and performance of the CoreValve™ system in a routine clinical setting.

Study Status/Duration: 5-year outcomes reported/5-year follow-up
Sample Size: N = 1,015
Devices: CoreValve, TAV

SEE STUDY DATA

Graph showing effective orifice area and mean gradient over 5 years.
View Larger

Key Medtronic trials

Review the latest data supporting the Evolut™ platform.

Explore the data

Procedure and performance

Discover our procedural guidance and outcomes you can expect from the Evolut™ platform.

Explore the technique
*

™Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

References

1

Harvey JE. Decreasing Permanent Pacemaker Implantation Rates in the STS/ACC TVT Registry with a Supra-annular Self-expanding Transcatheter Heart Valve. Presented at TVT2022; June 9, 2022; Chicago, IL.

2

Bajwa T, Rammohan C, Puri R, et al. The next-generation self-expanding transcatheter device: 30-day outcomes from the TVT-Registry. Presented at EuroPCR2021; May 2021.